Want to see TSE:LABS full AI Analyst Report?
MediPharm Labs (LABS) AI Stock Analysis
Top Page
MediPharm Labs
(TSX:LABS)
The score is held back primarily by weak financial performance (still unprofitable with negative TTM cash flow and declining revenue) and bearish technicals (below major moving averages with negative MACD). Offsetting these, the earnings call points to meaningful operational improvement (positive EBITDA and quarterly net income, higher margins, and lower opex), while valuation support is limited because earnings are negative and no dividend yield is provided.
MediPharm Labs (LABS) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 20.93M
- Dividend Yield
- ―
- Average Volume (3M)
- 129.34K
- Price to Earnings (P/E)
- -5.6
- Beta (1Y)
- 0.74
- Revenue Growth
- -6.74%
- EPS Growth
- 43.54%
- Country
- Canada
- Employees
- 127
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
MediPharm Labs Business Overview & Revenue Model
Company Description
MediPharm Labs Corp. operates as a pharmaceutical entity, specializing in the creation and global commercialization of premium, pharmaceutical-grade cannabis oils, concentrates, and sophisticated derivative products. Its market reach extends across C...
MediPharm Labs Earnings Call Summary
The call emphasized strong operational and financial recovery: return to profitability, highest adjusted EBITDA since 2019, robust margin expansion, meaningful sequential revenue growth driven by international markets (notably Germany), successful Phase II LiBBY clinical results validating the pharmaceutical platform, and balance sheet strength. Headwinds include a material 30% VAC reimbursement cut that reduced Canadian medical revenue, ongoing pricing pressure and competition in key markets (Germany), and broader prescribing/reimbursement uncertainties. Overall, the positive operational execution, clinical validation, and improved profitability notably outweigh the identified challenges.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management's guidance emphasized disciplined, margin‑focused growth in 2026 and beyond—prioritizing regulated medical markets, selective M&A, geographic expansion (France, Brazil, New Zealand, U.K.), and non‑smokable/pharma formats (oils and a metered‑dose inhaler dossier submitted). They pointed to Q2 metrics that underpin this plan: revenue of $10.0M (+11% sequential), international medical $5.8M (~58% of revenue, +26% sequential) with Germany +45% sequential/+33% YoY, Canadian medical $2.3M (from $3.0M), Canadian adult use $1.5M (+34% sequential); gross profit $4.3M (43% margin, +30% vs Q1, +13% YoY); operating expenses $4.0M (‑44% YoY, ‑4% sequential); adjusted EBITDA +$0.9M (second consecutive positive quarter, best since 2019) and positive net income (first profitable quarter since 2019). They also reiterated balance‑sheet flexibility to fund growth with $9.9M cash, virtually no debt, ownership of 2 facilities appraised >$15M, Q1 restructuring to deliver >$1M annualized savings, plans to mitigate the VAC reimbursement cut (30% reduction from $8.50 to $6/gram) via cost, supply‑chain and mix actions, and expected H2 shipments/replenishments for Brazil and New Zealand.
MediPharm Labs Financial Statement Overview
Summary
Mixed fundamentals: the balance sheet is strong with extremely low leverage (debt-to-equity ~0.01), but the latest TTM still shows declining revenue (-4.2% YoY), ongoing net losses (TTM net margin ~-12%), and negative operating/free cash flow despite improved cash burn versus 2025.
Income Statement
32NegativeBalance Sheet
74PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 41.46M | 45.12M | 41.96M | 33.06M | 22.12M | 21.71M |
| Gross Profit | 14.22M | 13.97M | 12.80M | 5.86M | -1.91M | -15.25M |
| EBITDA | -3.50M | -6.54M | -7.52M | -10.48M | -27.09M | -38.55M |
| Net Income | -4.97M | -8.27M | -10.69M | -13.08M | -29.98M | -54.80M |
Balance Sheet | ||||||
| Total Assets | 45.99M | 45.74M | 53.73M | 63.94M | 65.50M | 92.36M |
| Cash, Cash Equivalents and Short-Term Investments | 9.85M | 10.81M | 11.69M | 17.98M | 24.14M | 34.11M |
| Total Debt | 421.00K | 201.00K | 388.00K | 2.29M | 632.00K | 216.00K |
| Total Liabilities | 10.56M | 9.93M | 10.55M | 10.93M | 9.49M | 9.21M |
| Stockholders Equity | 35.43M | 35.81M | 43.18M | 53.01M | 56.01M | 83.15M |
Cash Flow | ||||||
| Free Cash Flow | -960.00K | -5.60M | -5.01M | -12.81M | -16.93M | -14.00M |
| Operating Cash Flow | -897.00K | -5.50M | -4.86M | -12.34M | -16.07M | -13.21M |
| Investing Cash Flow | 412.00K | 4.62M | 413.00K | 6.87M | 5.16M | 35.00K |
| Financing Cash Flow | -37.00K | -18.00K | -1.85M | -368.00K | 796.00K | 27.80M |
MediPharm Labs Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LABS, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 43.30 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:LABS.
MediPharm Labs Peers Comparison
Overall Rating
TSE:INNO56Neutral- TSE:LABS49Neutral
TSE:OILS45Neutral
TSE:ROMJ45Neutral
TSE:AVCN41Neutral
TSE:PCLO24Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:INNO | 56Neutral | CAD 8.55M | -6.55 | -19.37% | ― | -19.20% | 42.54% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:LABS | 49Neutral | CAD 27.77M | -5.60 | -13.79% | ― | -6.74% | 43.54% |
| TSE:OILS | 45Neutral | CAD 3.40M | -1.75 | -43.92% | ― | -18.30% | -397.37% |
| TSE:ROMJ | 45Neutral | CAD 25.34M | -15.24 | -4.00% | ― | 16.66% | -1007.41% |
| TSE:AVCN | 41Neutral | CAD 14.11M | -3.24 | -108.44% | ― | -0.23% | -142.54% |
| TSE:PCLO | 24Underperform | CAD 9.34M | -2.67 | 28.59% | ― | 0.90% | 57.73% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:LABS | Medipharm Labs (Otc) | 0.07 | -0.01 | -13.33% | |
| TSE:PCLO | Pharmacielo | 0.05 | 0.01 | 11.11% | |
| TSE:OILS | Nextleaf Solutions | 0.02 | -0.04 | -66.67% | |
| TSE:ROMJ | Rubicon Organics | 0.38 | -0.13 | -25.00% | |
| TSE:AVCN | Avicanna Inc | 0.10 | -0.16 | -60.38% | |
| TSE:INNO | Innocan Pharma Corporation | 1.90 | -16.10 | -89.44% |
MediPharm Labs Corporate Events
MediPharm Labs Enters Panama with CBD Inhaler as Latin American Medical Cannabis Market Accelerates
PositiveMediPharm Labs has entered Panama’s medical cannabis market with its first commercial shipment of CBD metered-dose inhalers to local partner Adeiwa Pharma, expanding an international footprint that already spans more than 10 countries. The smok...
MediPharm Labs Sets Date for Q2 2026 Results Amid Global Medical Cannabis Expansion
PositiveMediPharm Labs has scheduled the release of its second-quarter 2026 financial results for August 13, 2026, before markets open, and will host a conference call and webcast later that morning to discuss performance. The company will also provide inves...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026